Simulations Plus Announces Cash Dividend
10/13/2021 - 08:30 AM
Board of Directors announces quarterly dividend of $0.06 per share
LANCASTER, Calif. --(BUSINESS WIRE)--
Simulations Plus, Inc. (Nasdaq: SLP) announced today that the Company’s Board of Directors has declared a cash dividend of $0.06 per share of the Company’s common stock, payable on November 1, 2021 , to shareholders of record as of October 25, 2021 . The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.
About Simulations Plus, Inc.
Serving clients worldwide for 25 years, Simulations Plus, Inc. is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. We offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com . Follow us on Twitter | Read our Environmental, Social, and Governance (ESG) Report .
View source version on businesswire.com : https://www.businesswire.com/news/home/20211013005362/en/
Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee@simulations-plus.com
Hayden IR
Mr. Brian Siegel
346-396-8696
brian@haydenir.com
Source: Simulations Plus, Inc.
Simulations Plus Inc.
NASDAQ:SLP
SLP Rankings
#3207 Ranked by Stock Gains
SLP Stock Data
Industry
Computer Systems Design Services
Sector
Professional, Scientific, and Technical Services
Tags
Technology Services, Packaged Software, Professional, Scientific, and Technical Services, Computer Systems Design Services
Country
US
City
Lancaster
About SLP
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res